Evidence map›Paper›PMID 39292288›Full record

ArticleWorld journal of urology2024

Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.

Masaki Shiota, Nobuaki Matsubara, Taigo Kato, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Koshiro Nishimoto, Yota Yasumizu, Nobuyuki Tanaka and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.
Nobuaki MatsubaraDepartment Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Taigo KatoDepartment of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Takahiro OsawaDepartment of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Takashige AbeDepartment of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Nobuo ShinoharaDepartment of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Koshiro NishimotoDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yota YasumizuDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Nobuyuki TanakaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Takao FujisawaDepartment Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Satoshi HorasawaTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Norio NonomuraDepartment of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUndetectable circulating tumor DNA (ctDNA) is an obstacle to performing comprehensive genomic profiling in daily practice to identify genomic alterations. We investigated the associations between clinicopathological factors and undetectable ctDNA using a commercially available comprehensive genomic profiling assay in metastatic prostate cancer. PATIENTS AND

methodsPatients treated with systemic treatment for metastatic prostate cancer were included. ctDNA was analyzed by FoundationOne

resultsThe number of bone metastasis was associated with ctDNA detection (odds ratio [95% confidence interval], 13.6 [1.71-108], P = 0.014). An algorithm predicting ctDNA detection using clinicopathological parameters was created. If ≥ 4 bone metastases were observed, ctDNA detection was estimated to be 98.9%. Among the patients with < 4 bone metastases, if two or three features among ISUP grade group 5, PSA level ≥ 10 ng/ml, and castration resistance were present, the ctDNA detection rate was 96.7% while the ctDNA detection rate was 86.3% if no or only one feature was present.

conclusionsAn algorithm created in this study is helpful in determining when to undertake comprehensive genomic profiling assay using blood.

Indexed as

Circulating Tumor DNAProstatic NeoplasmsAgedAged, 80 and overAlgorithmsBone NeoplasmsGenomicsHumansJapanMaleMiddle AgedPredictive Value of TestsCirculating Tumor DNACirculating tumor DNADetectionMetastatic prostate cancer

Identifiers

PMID39292288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.